On Monday, Denali Therapeutics Inc (NASDAQ: DNLI) was -6.16% drop from the session before settling in for the closing price of $22.25. A 52-week range for DNLI has been $14.56 – $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 350.08% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -162.11%. With a float of $124.56 million, this company’s outstanding shares have now reached $143.84 million.
In an organization with 445 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.45%, while institutional ownership is 87.93%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -162.11% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.02 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was inferior than the volume of 1.02 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.37%. Additionally, its Average True Range was 1.34.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 15.94%, which indicates a significant decrease from 16.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.14% in the past 14 days, which was lower than the 60.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.42, while its 200-day Moving Average is $23.48. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $22.07. Second resistance stands at $23.27. The third major resistance level sits at $24.19. If the price goes on to break the first support level at $19.95, it is likely to go to the next support level at $19.03. Assuming the price breaks the second support level, the third support level stands at $17.83.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are 143,922K outstanding shares of the company, which has a market capitalization of 3.01 billion. As of now, sales total 330,530 K while income totals -145,220 K. Its latest quarter income was 0 K while its last quarter net income were -107,190 K.
